H.I.G. BIOHEALTH PARTNERS

H.I.G. BioHealth Partners Co-Leads a $52M Financing for Click Therapeutics

Retrieved on: 
Tuesday, October 26, 2021
Banking, Software, General Health, Networks, Professional Services, Internet, Data Management, Technology, Science, Finance, Other Technology, Health, Other Science, Major depressive disorder, Otsuka Pharmaceutical, CNI, Entrepreneurship, H.I.G. Capital, Patient, Click, Boehringer Ingelheim, Venture round, Company, Verily, Clinical trial, CEO, Chronic pain, Psychiatry, Schizophrenia, Therapy, MDD, Pharmaceutical industry, Click Therapeutics, H.I.G. BioHealth Partners, CLICK THERAPEUTICS, H.I.G. BIOHEALTH PARTNERS

The Series B financing will be used to advance clinical development and commercialization of Clicks prescription digital therapeutics pipeline.

Key Points: 
  • The Series B financing will be used to advance clinical development and commercialization of Clicks prescription digital therapeutics pipeline.
  • BioHealth Partners will join the board of Click.
  • Clicks pipeline of innovative digital therapeutics spans multiple therapeutic areas, from psychiatry and chronic pain, to cardiometabolic and autoimmune disorders.
  • Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for patients with unmet medical needs.

Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners

Retrieved on: 
Friday, October 22, 2021
Biotechnology, Alternative Medicine, Physical Therapy, Technology, Professional Services, Other Health, Health, Mental Health, Software, Mobile, Wireless, Finance, Digital, Series, Major depressive disorder, CNI, Technology, Entrepreneurship, Director, Industry, Association of British HealthTech Industries, H.I.G. Capital, Patient, Click, Boehringer Ingelheim, Ōtsuka, Verily, Clinical trial, CEO, Chronic pain, Growth, Psychiatry, Schizophrenia, Therapy, MDD, Pharmaceutical industry, Click Therapeutics, H.I.G. BioHealth Partners, Accelmed Partners, CLICK THERAPEUTICS, H.I.G. BIOHEALTH PARTNERS, ACCELMED PARTNERS

Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing.

Key Points: 
  • Click Therapeutics, Inc. (Click), a leader in Digital Therapeutics as prescription medical treatments, today announced that it has closed a $52 million upsized Series B financing.
  • Proceeds from the Series B financing will be used to accelerate the development and commercialization of Clicks internal prescription digital therapeutic pipeline and advance Clicks platform capabilities.
  • Clicks pipeline of innovative digital therapeutics spans multiple therapeutic areas, from psychiatry and chronic pain to cardiometabolic and autoimmune disorders.
  • In conjunction with the Series B financing, Clicks Board of Directors will expand to include Alex Zisson, Managing Director at H.I.G.